Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

101. Pegfilgrastim (Udenyca) - used in cancer patients to help with neutropenia

Pegfilgrastim (Udenyca) - used in cancer patients to help with neutropenia 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. EMA/518623/2018 EMEA/H/C/004413 Udenyca (pegfilgrastim) An overview of Udenyca and why it is authorised (...) in the EU What is Udenyca and what is it used for? Udenyca is a medicine used in cancer patients to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer treatment and can leave patients vulnerable to infections. It is given specifically to reduce the duration of neutropenia and prevent febrile neutropenia (when neutropenia is accompanied by fever). Udenyca is not intended for use in patients with the blood cancer chronic myeloid leukaemia

European Medicines Agency - EPARs2018

102. Abemaciclib (Verzenios) - breast cancer

Abemaciclib (Verzenios) - breast cancer 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. EMA/521639/2018 EMEA/H/C/004302 Verzenios (abemaciclib) An overview of Verzenios and why it is authorised in the EU What is Verzenios and what (...) is it used for? Verzenios is a cancer medicine used to treat women with breast cancer that is advanced or has spread to other parts of the body. Verzenios can only be used when the cancer cells have certain types of receptor (called hormone receptors) on their surface (HR-positive) and do not produce abnormally large quantities of another receptor called HER2 (HER2-negative). It is used together with a hormonal medicine, either an aromatase inhibitor or fulvestrant. In women who have not yet reached

European Medicines Agency - EPARs2018

103. Pegfilgrastim (Pelgraz) - used in cancer patients to help with neutropenia

Pegfilgrastim (Pelgraz) - used in cancer patients to help with neutropenia 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. EMA/610949/2018 EMEA/H/C/003961 Pelgraz (pegfilgrastim) An overview of Pelgraz and why it is authorised (...) in the EU What is Pelgraz and what is it used for? Pelgraz is a medicine used in cancer patients to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer treatment and can leave patients vulnerable to infections. It is given specifically to reduce the duration of neutropenia and prevent febrile neutropenia (when neutropenia is accompanied by fever). Pelgraz is not intended for use in patients with the blood cancer chronic myeloid leukaemia

European Medicines Agency - EPARs2018

104. Guidance for Kyphoplasty and Vertebroplasty for Cancer Patients in Ontario

Guidance for Kyphoplasty and Vertebroplasty for Cancer Patients in Ontario GUIDANCE FOR KYPHOPLASTY AND VERTEBROPLASTY FOR CANCER PATIENTS IN ONTARIO: Recommendations Report 2017 Kyphoplasty and Vertebroplasty Working Group Interventional Oncology Steering Committee Page 1 of 16 Document Date: October 5, 2018 Contents Background 2 Value for Money 2 Recommendations for Vertebral Augmentation involving Kyphoplasty or Vertebroplasty for Cancer-Related Vertebral Compression Fractures 3 Clinical (...) Criteria 3 Rationale 4 Role of Radiation Treatment 4 Absolute Contraindications 4 Service Provider Requirements 4 Multidisciplinary Care 4 Volume Recommendations 7 Training Recommendations 8 Quality Assurance 8 Conclusions 8 References 9 Appendices 10 Appendix A: Kyphoplasty and Vertebroplasty Working Group Members 10 Appendix B: Malignant Potential Diagnosis Codes 10 Appendix C: Kyphoplasty and Vertebroplasty for Cancer Patients Referral Checklist 13 Document Revision History Document Date Revision

Cancer Care Ontario2018

105. Bevacizumab (Mvasi) - Metastatic Colorectal Cancer (mCRC) or Locally Advanced, Metastatic or Recurrent Non-small Cell Lung Cancer (NSCLC)

Bevacizumab (Mvasi) - Metastatic Colorectal Cancer (mCRC) or Locally Advanced, Metastatic or Recurrent Non-small Cell Lung Cancer (NSCLC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for is located

Health Canada - Drug and Health Product Register2018

106. Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use

Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use - GOV.UK GOV.UK uses cookies to make the site simpler. Search Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use Advise patients taking hydrochlorothiazide-containing products of the cumulative, dose-dependent risk of non-melanoma skin cancer, particularly in long-term use, and the need (...) to regularly check for (and report) any suspicious skin lesions or moles. Counsel patients to limit exposure to sunlight and UV rays and to use adequate sun protection. Published 14 November 2018 From: Therapeutic area: , , , Contents Advice for healthcare professionals: pharmacoepidemiological studies have shown a dose-dependent increased risk of non-melanoma skin cancer (basal cell carcinoma [BCC] and squamous cell carcinoma [SCC], including SCC lip cancer) with exposure to increasing cumulative doses

MHRA Drug Safety Update2018

107. Talazoparib (Talzenna) - For the treatment of locally advanced or metastatic breast cancer patients with a germline BRCA mutation

Talazoparib (Talzenna) - For the treatment of locally advanced or metastatic breast cancer patients with a germline BRCA mutation Drug Approval Package: Talzenna (talazoparib) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Talzenna (talazoparib) Company: Pfizer, Inc Application Number: 211651 Approval Date: 10/16/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter

FDA - Drug Approval Package2018

108. Diagnosis, Assessment and Management of Constipation in Advanced Cancer: ESMO Clinical Practice Guidelines

Diagnosis, Assessment and Management of Constipation in Advanced Cancer: ESMO Clinical Practice Guidelines CLINICAL PRACTICE GUIDELINES Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines † P. J. Larkin 1,2 , N. I. Cherny 3 , D. La Carpia 4 , M. Guglielmo 5 , C. Ostgathe 6 , F. Scotte ´ 7 & C. I. Ripamonti 5 ,on behalf of the ESMO Guidelines Committee * 1 School of Nursing, Midwifery and Health Systems, University College Dublin, Dublin; 2 (...) Our Lady’s Hospice and Care Services, Dublin, Ireland; 3 Cancer Pain and Palliative Medicine Service, Department of Oncology, Shaare Zedek Medical Center, Jerusalem, Israel; 4 Centro Medicina Dell’Invecchiamento (Ce.M.I.), Fondazione Policlinico Agostino, Gemelli, Roma; 5 Oncology-Supportive Care Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy; 6 Palliative Care Department, University Hospital Erlangen, Friedrich-Alexander-Universita ¨t Erlangen-Nu ¨rnberg, Erlangen, Germany; 7

European Society for Medical Oncology2018

109. Durvalumab (Imfinzi) - non-small cell lung cancer (NSCLC)

Durvalumab (Imfinzi) - non-small cell lung cancer (NSCLC) 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. EMA/521637/2018 EMEA/H/C/004771 Imfinzi (durvalumab) An overview of Imfinzi and why it is authorised in the EU What (...) is Imfinzi and what is it used for? Imfinzi is a medicine used to treat a type of lung cancer called non-small cell lung cancer (NSCLC). Imfinzi is used in adult patients with advanced cancer that cannot be removed by surgery but is not getting worse after treatment with radiation and platinum-based chemotherapy (medicines to treat cancer). Imfinzi is used specifically when the tumour produces a protein known as PD-L1. Imfinzi contains the active substance durvalumab. How is Imfinzi used? Imfinzi

European Medicines Agency - EPARs2018

110. Hypofractionated Radiation Therapy for Localized Prostate Cancer

Hypofractionated Radiation Therapy for Localized Prostate Cancer ');//--> ');//--> Search in: Menu COOKIES REQUIRED In order to access this website, please configure your browser to support cookies. ASCO Family of Sites Journals Publications Education Other Sites 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2018 American Society of Clinical Oncology |

American Society of Clinical Oncology Guidelines2018

111. Lung Cancer Screening

Lung Cancer Screening New 2018 ACR Appropriateness Criteria ® 1 Lung Cancer Screening American College of Radiology ACR Appropriateness Criteria ® Lung Cancer Screening Variant 1: Lung cancer screening. Patient 55 to 80 years of age and 30 or more packs per year smoking history and currently smoke or have quit within the past 15 years. Procedure Appropriateness Category Relative Radiation Level CT chest without IV contrast screening Usually Appropriate ??? CT chest with IV contrast Usually (...) Not Appropriate ??? CT chest without and with IV contrast Usually Not Appropriate ??? FDG-PET/CT skull base to mid-thigh Usually Not Appropriate ???? MRI chest without and with IV contrast Usually Not Appropriate O MRI chest without IV contrast Usually Not Appropriate O Radiography chest Usually Not Appropriate ? Variant 2: Lung cancer screening. Patient 50 years of age or older and 20 or more packs per year history of smoking and one additional risk factor (ie, radon exposure or occupational exposure

American College of Radiology2018

112. Leading Women's Health Care Groups Issue Joint Statement on USPSTF Final Cervical Cancer Screening Recommendations

Leading Women's Health Care Groups Issue Joint Statement on USPSTF Final Cervical Cancer Screening Recommendations

Society of Gynecologic Oncology2018

113. Fosaprepitant (Ivemend) - prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy

Fosaprepitant (Ivemend) - prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy Published 12 November 2018 1 www.scottishmedicines.org.uk Product update SMC2108 fosaprepitant 150mg powder for solution for infusion (Ivemend) MSD UK Ltd 05 October 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland (...) . The advice is summarised as follows: ADVICE: following an abbreviated submission fosaprepitant (Ivemend 150mg ® ) is accepted for use within NHSScotland. Indication under review: prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in paediatric patients aged 6 months to 17 years. Fosaprepitant is given as part of a combination therapy. SMC has previously accepted fosaprepitant as part of combination therapy for the prevention of acute and delayed nausea

Scottish Medicines Consortium2018

114. Dental radiograph as an opportunistic screening tool for a colorectal cancer syndrome (CAT#3342)

Dental radiograph as an opportunistic screening tool for a colorectal cancer syndrome (CAT#3342) UTCAT3342, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Dental radiograph as an opportunistic screening tool for a colorectal cancer syndrome Clinical Question Does dental radiograph serve as an opportunistic screening tool for early detection of extraintestinal manifestations of Familial Adenomatous Polyposis (FAP (...) ) in children and adults? Clinical Bottom Line Incidental findings on dental radiographs could serve as screening tools for systemic diseases and syndromes. The attention should be raised when gene mutation, congenitally diseases or familial colorectal cancer are reported by patients during the medical history questionnaire. For patients with risk of FAP, the Dental panoramic radiographic score (DPRS) is inexpensive, and reinforce the referral for the further clinical investigation, gene mapping

UTHSCSA Dental School CAT Library2018

115. Implant Based Breast Reconstruction With Acellular Dermal Matrix: Safety Data From an Open-label, Multicenter, Randomized, Controlled Trial in the Setting of Breast Cancer Treatment

Implant Based Breast Reconstruction With Acellular Dermal Matrix: Safety Data From an Open-label, Multicenter, Randomized, Controlled Trial in the Setting of Breast Cancer Treatment 30308615 2018 10 19 1528-1140 2018 Oct 17 Annals of surgery Ann. Surg. Implant Based Breast Reconstruction With Acellular Dermal Matrix: Safety Data From an Open-label, Multicenter, Randomized, Controlled Trial in the Setting of Breast Cancer Treatment. 10.1097/SLA.0000000000003054 To evaluate clinical outcomes (...) of using acellular dermal matrix (ADM) with implant based breast reconstructions (IBBRs) in a randomized controlled trial. The use of ADMs in IBBRs is widespread, but link between ADM and complications remain a controversial topic. In view of reports concerning harm, we present 6-months safety data of ADM-assisted IBBR in the setting of breast cancer treatment. An open-label, randomized, controlled trial recruiting patients from 4 centers in Sweden and 1 in UK. Eligible were women with breast cancer

EvidenceUpdates2018

116. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy

A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy 30237023 2018 11 17 1873-7560 74 6 2018 Dec European urology Eur. Urol. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial (...) Biopsy. 731-738 S0302-2838(18)30604-3 10.1016/j.eururo.2018.08.019 Discriminating indolent from clinically significant prostate cancer (PCa) in the initial biopsy setting remains an important issue. Prospectively evaluated diagnostic assays are necessary to ensure efficacy and clinical adoption. Performance and utility assessment of ExoDx Prostate (IntelliScore) (EPI) urine exosome gene expression assay versus standard clinical parameters for discriminating Grade Group (GG) ≥2 PCa from GG1 PCa

EvidenceUpdates2018

117. Population health interventions to improve colorectal cancer screening by fecal immunochemical tests: A systematic review

Population health interventions to improve colorectal cancer screening by fecal immunochemical tests: A systematic review 30367972 2018 11 16 1096-0260 118 2018 Oct 24 Preventive medicine Prev Med Population health interventions to improve colorectal cancer screening by fecal immunochemical tests: A systematic review. 113-121 S0091-7435(18)30340-2 10.1016/j.ypmed.2018.10.021 Despite clear evidence that colorectal cancer (CRC) screening reduces mortality, screening, including fecal (...) preventative services, and provider alerts) have the potential to significantly increase screening participation. However, such programs must also follow-up patients with abnormal FIT results. Copyright © 2018 Elsevier Inc. All rights reserved. Issaka Rachel B RB Clinical Research & Public Health Sciences Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America; Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA, United

EvidenceUpdates2018

118. OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients

OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients 30333540 2018 10 18 1572-0241 2018 Oct 17 The American journal of gastroenterology Am. J. Gastroenterol. OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients. 10.1038/s41395-018-0353-8 Gastritis OLGA-staging ranks the risk for gastric cancer (GC) in progressive stages (0-IV). This long-term follow-up study quantifies the GC risk (...) associated with each OLGA stage. Consecutive patients (7436) underwent esophagogastroscopy (T-0), with mapped gastric biopsies, OLGA staging, and H. pylori status assessment. Patients with neoplastic lesion (invasive or non-invasive) at the index endoscopy (and/or within 12 months) were excluded. All patients were followed-up (T-1) by combining different sources of clinical/pathological information (Regional Registries of: (i) esophagogastroduodenoscopies; (ii) pathology reports; (iii) cancer, (iv

EvidenceUpdates2018

119. Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer

Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer 30286948 2018 10 05 1873-7560 2018 Oct 01 European urology Eur. Urol. Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. S0302-2838(18)30549-9 10.1016/j.eururo.2018.07.027 Systemic therapies, combined with local treatment for high-risk prostate cancer, are recommended (...) by the international guidelines for specific subgroups of patients; however, for many of the clinical scenarios, it remains a research field. To perform a systematic review, and describe current evidence and perspectives about the multimodal treatment of high-risk prostate cancer. We performed a systematic review of PubMED, Embase, Cochrane Library, European Society of Medical Oncology/American Society of Clinical Oncology Annual proceedings, and clinicalTrial.gov between January 2010 and February 2018 following

EvidenceUpdates2018

120. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study 30262187 2018 09 28 1474-5488 2018 Sep 21 The Lancet. Oncology Lancet Oncol. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. S1470-2045(18)30673-9 10.1016/S1470-2045(18)30673-9 Antibodies targeting the immune checkpoint molecules PD (...) -1 or PD-L1 have demonstrated clinical efficacy in patients with metastatic non-small-cell lung cancer (NSCLC). In this trial we investigated the efficacy and safety of avelumab, an anti-PD-L1 antibody, in patients with NSCLC who had already received platinum-based therapy. JAVELIN Lung 200 was a multicentre, open-label, randomised, phase 3 trial at 173 hospitals and cancer treatment centres in 31 countries. Eligible patients were aged 18 years or older and had stage IIIB or IV or recurrent NSCLC

EvidenceUpdates2018